Loading...
•
Dec 31, 2020
Esperion Q4 2020 Earnings Report
Esperion reported Q4 2020 financial results, highlighting U.S. product revenue of $8.2 million and progress in the CLEAR Outcomes Study.
Key Takeaways
Esperion reported a total revenue of $9.6 million for Q4 2020, driven by U.S. product revenue of $8.2 million. The company's net loss was $104.5 million. They made progress on the CLEAR Outcomes trial and strengthened their balance sheet.
U.S. product revenue reached $8.2 million, a 150% increase compared to the third quarter.
Over 21,000 patients are on NEXLETOL and NEXLIZET in the U.S.
The CLEAR Outcomes Study design was highlighted in The American Heart Journal and progresses uninterrupted despite the pandemic.
The company adjusted its commercial and operational footprint and optimized its cost structure.
Revenue by Segment
Forward Guidance
Esperion expects full-year 2021 operating expenses to be approximately $320 million to $340 million, inclusive of $30 million of non-cash, stock-based compensation. Research and development expenses for the full year 2021 are expected to be $120 million to $130 million. Selling, general and administrative expenses for the full year 2021 are expected to be $200 million to $210 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...